Has Boston Scientific Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Boston Scientific (NYSE: BSX  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Boston Scientific.

Factor

What We Want to See

Actual

Pass or Fail?

Growth 5-Year Annual Revenue Growth > 15% 1.3% Fail
  1-Year Revenue Growth > 12% (1.4%) Fail
Margins Gross Margin > 35% 64.0% Pass
  Net Margin > 15% 7.3% Fail
Balance Sheet Debt to Equity < 50% 37.0% Pass
  Current Ratio > 1.3 1.70 Pass
Opportunities Return on Equity > 15% 5.1% Fail
Valuation Normalized P/E < 20 16.87 Pass
Dividends Current Yield > 2% 0% Fail
  5-Year Dividend Growth > 10% 0% Fail
       
  Total Score   4 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Boston Scientific last year, the maker of medical devices has gotten up off the mat and quadrupled its score. An improving balance sheet and a falling valuation helped account for the jump, although the stock hasn't performed well for quite a while.

Boston Scientific focuses on a range of medical devices, including heart defibrillators, catheters, and stents. Those industries have no lack of competition, with Abbott Labs (NYSE: ABT  ) , St. Jude Medical (NYSE: STJ  ) , and Medtronic (NYSE: MDT  ) among the companies with similar product lines.

But the big problem that Boston Scientific has is an ongoing inability to execute on a turnaround that has lasted for years. After making several strategic mistakes and leadership changes, the company grabbed up former Johnson & Johnson (NYSE: JNJ  ) medical device group chairman Michael Mahoney. But due to a non-compete agreement, Mahoney won't be able to assume the CEO role until late next year, putting the company in the awkward position of having an interim CEO for just over a year. Unlike Medtronic, which found General Electric (NYSE: GE  ) health-care CEO Omar Ishrak to replace the exiting William Hawkins, Boston Scientific's choice to replace former CEO Ray Elliot isn't going to be the smoothest transition ever.

In the long run, Boston Scientific may finally get over its long-term problems. But having failed to take advantage of an obvious potential catalyst, the company doesn't look much closer to getting out of its restructuring woes. Until it does, it's hard to see Boston Scientific making much more progress toward perfection.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Click here to add Boston Scientific to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Finding the perfect stock is only one piece of a successful investment strategy. Get the big picture by taking a look at our "13 Steps to Investing Foolishly."

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned. The Motley Fool owns shares of Medtronic, St. Jude Medical, Abbott Labs, and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Abbott Labs, as well as creating a diagonal call position in Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1740771, ~/Articles/ArticleHandler.aspx, 12/21/2014 4:32:18 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement